Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/Oral-ta

Discover the world at Altruu, The Discovery Engine